Arbutus Biopharma

ABUS-Q

Analysis and Opinions about ABUS-Q

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
January 28, 2015

They are known for their Ebola treatment but people lost interest in them and the stock started to sell off. They then made a deal, but he wonders if it was made in order to prop up the share price. Wouldn’t Buy the stock here as it is pretty expensive and it is not proven yet.

Show full opinionHide full opinion
Arbutus Biopharma (ABUS-Q)
January 28, 2015

They are known for their Ebola treatment but people lost interest in them and the stock started to sell off. They then made a deal, but he wonders if it was made in order to prop up the share price. Wouldn’t Buy the stock here as it is pretty expensive and it is not proven yet.

COMMENT
COMMENT
January 14, 2015

He has to be careful, because one drug could be a home run, but he has stayed away because it is so hard to predict how drugs will do through the whole approval process. You get a product that looks very promising through the first few stages of testing and trials. Right at the end, when they do the large scale trials, something turns up that hasn’t been seen in the smaller trials. To bring a new drug through the approval process is upwards of $1 billion. Because of this, they usually end up partnering with a big Pharma, and the value goes to the big Pharma.

Show full opinionHide full opinion
Arbutus Biopharma (ABUS-Q)
January 14, 2015

He has to be careful, because one drug could be a home run, but he has stayed away because it is so hard to predict how drugs will do through the whole approval process. You get a product that looks very promising through the first few stages of testing and trials. Right at the end, when they do the large scale trials, something turns up that hasn’t been seen in the smaller trials. To bring a new drug through the approval process is upwards of $1 billion. Because of this, they usually end up partnering with a big Pharma, and the value goes to the big Pharma.

COMMENT
COMMENT
October 28, 2014

This company works on Ebola treatments. A stock like this is driven by news. There is seasonality to biotechs from June 23 to September 13, but in this case there is too much news going on.

Show full opinionHide full opinion
Arbutus Biopharma (ABUS-Q)
October 28, 2014

This company works on Ebola treatments. A stock like this is driven by news. There is seasonality to biotechs from June 23 to September 13, but in this case there is too much news going on.

SELL
SELL
October 21, 2014

Doesn’t know exactly what is going to happen with the treatment of Ebola. The stock has had a tremendous run. They are miles away from being a valuation story at this point. If you have made some money in the stock, he would be inclined to take profits and move on.

Show full opinionHide full opinion
Arbutus Biopharma (ABUS-Q)
October 21, 2014

Doesn’t know exactly what is going to happen with the treatment of Ebola. The stock has had a tremendous run. They are miles away from being a valuation story at this point. If you have made some money in the stock, he would be inclined to take profits and move on.

DON'T BUY
DON'T BUY
October 17, 2014

It is up a lot, but it is just so speculative. It is not his cup of tea. If the outbreak of Ebola starts to come under control, then this stock should decline back down.

Show full opinionHide full opinion
Arbutus Biopharma (ABUS-Q)
October 17, 2014

It is up a lot, but it is just so speculative. It is not his cup of tea. If the outbreak of Ebola starts to come under control, then this stock should decline back down.

DON'T BUY
DON'T BUY
August 26, 2014

A play on ebola could have a nice kick up now, but looking at the financials, they have lost money in 8 out of the last 10 years. This does not bode well. Also, they are not at all close to getting the product into the market. The testing for their product was actually for another product, so they are going to have to have a certain amount of latitude in getting it out. He would prefer Alpha Pro Tech (APT-A).

Show full opinionHide full opinion

A play on ebola could have a nice kick up now, but looking at the financials, they have lost money in 8 out of the last 10 years. This does not bode well. Also, they are not at all close to getting the product into the market. The testing for their product was actually for another product, so they are going to have to have a certain amount of latitude in getting it out. He would prefer Alpha Pro Tech (APT-A).

DON'T BUY
DON'T BUY
August 12, 2014

Working on an experimental Ebola treatment. The biotech sector is probably the most volatile sector that you can get involved with. He would never buy just one biotech stock; he would buy a basket of 3, maybe 5. He wouldn’t touch this one. Too volatile and too risky.

Show full opinionHide full opinion

Working on an experimental Ebola treatment. The biotech sector is probably the most volatile sector that you can get involved with. He would never buy just one biotech stock; he would buy a basket of 3, maybe 5. He wouldn’t touch this one. Too volatile and too risky.

Showing 1 to 7 of 7 entries
  • «
  • 1
  • »

Arbutus Biopharma(ABUS-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Arbutus Biopharma is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Arbutus Biopharma(ABUS-Q) Frequently Asked Questions

What is Arbutus Biopharma stock symbol?

Arbutus Biopharma is a American stock, trading under the symbol ABUS-Q on the NASDAQ (ABUS). It is usually referred to as NASDAQ:ABUS or ABUS-Q

Is Arbutus Biopharma a buy or a sell?

In the last year, there was no coverage of Arbutus Biopharma published on Stockchase.

Is Arbutus Biopharma a good investment or a top pick?

Arbutus Biopharma was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Arbutus Biopharma.

Why is Arbutus Biopharma stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Arbutus Biopharma worth watching?

In the last year, there was no coverage of Arbutus Biopharma published on Stockchase.

What is Arbutus Biopharma stock price?

On 2020-06-03, Arbutus Biopharma (ABUS-Q) stock closed at a price of $2.06.